Glaxo Group Limited

Smithkline Beecham Corporation

Gregor James MacDonald

Mervyn Thompson

Christopher Norbert Johnson

Stephen Frederick Moss

David Richard Witty

Mahmood Ahmed

Charles Edward Wade

Martin C Jones

Susan Marie Westaway

Harshad Kantilal Rami

Darren Jason Mitchell

Geoffrey Stemp

Michael S Hadley

Andrew Lightfoot

Antonio Kuok Keong Vong

Leontine Saskia Trouw

Disclosed are quinoline compounds having affinity for the 5-HTreceptor and having the formula: where R, R, R, R, R, n, m, p and A are defined herein, and salts thereof, compositions containing these compounds and salts and processes for making and using the same.

[object Object]

Quinoline derivatives and their use as 5-HT6 ligands

The present invention relates to novel biaryl derivatives such as compounds of formula (I), which have activity as agonists of the GPR38 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of gastrointestinal disorders.

Biaryl compounds useful as agonists of the Gpr38 receptor

The present invention relates to novel quinoline compounds having pharmacological activity, to processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.

Certain compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R, R, R, P, X, Y, q, r ans s are as defined in the specification, a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds in medicine.

Vanilloid receptor modulators

Carboxamide derivatives

According to the invention there are provided compounds of formula (I) wherein R, p, P, n, s, r, W, P', t, Rand q are as defined in the specification, processes for preparing them and their use in therapy.

Urea derivatives having vanilloid receptor antagonist activity

Disclosed are novel quinoline compounds of formula (I), processes for their preparation, compositions containing them and their use in the treatment of CNS disorders. 

Quinoline derivatives and their use as 5-ht6 ligands

Disclosed is a method for use of phenyl sulfone compounds of formula (I) in the treatment of anxiety. 

Compounds

The invention provides compounds of formula (I): wherein: Rand Rindependently represent various substituents; Rand Rindependently represent H, F, Cl, Br, Calkyl, Calkoxy, OH, CN, or NO; B represents a sulfur atom or a &#x2014;CH-group; t represents 3 or 4; and A represents an optionally substituted 5- or 6-membered aromatic heterocyclic ring, or an optionally substituted bicyclic heterocyclic ring system in which at least the ring bound to the group B in Formula (I) is aromatic; or a salt thereof. Preferably, A is selected from one of the groups (i), (ii) or (iii): wherein Xand Xare independently N or CR, and Xis NR, O or S; Yand Yare independently N or CR, and Yis NR, O or S; Zis NR, O or S, and Zand Zare independently N or CR; R, R, and Rare as herein defined, and Ris H, a halogen atom, OH, cyano, nitro, Calkyl, Calkoxy, Calkylenedioxy, Calkanoyl, or Calkylsulfonyl, an optionally substituted 3-, 4-, 5- or 6-membered cycloalkyl ring, or a group of the formula (a), (b), (c) or (d) as defined by the formulas (a), (b), (c) or (d). The compounds are modulators of dopamine Dreceptors and have potential in the treatment of psychotic conditions (e.g. schizophrenia) or substance abuse.

Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents)

This invention relates to novel phenyl sulfone compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.

Growing community of inventors

Harlow, United Kingdom

Gregor James MacDonald